Thymoma

Reports on thymic cancer findings from X.F. Li and co-researchers provide new insights

Thymoma Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank dramatically. Moreover, the tumors showed stable disease for at least 9 months. To the best of our knowledge, it is the first report about a response of advanced thymic carcinoma to sorafenib," wrote X.F. Li and colleagues.

The researchers concluded: "The preliminary study suggested that molecular target-based therapy could be an alternative treatment to those chemotherapy-refractory patients."

Li and colleagues published their study in Medical Oncology (Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Medical Oncology, 2009;26(2):157-160).

For additional information, contact X.F. Li, Quanzhou Hospital Tradit Chinese Medical, Dept. of Oncology, 215 S Wenling Rd., Quanzhou 362000, People's Republic of China.

The publisher's contact information for the journal Medical Oncology is: Humana Press Inc., 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA.

Keywords: People's Republic of China, Quanzhou, Chemotherapy, Cisplatin, Drug Resistance, Drug Therapy, Drugs, Infectious Disease, Nexavar, Oncology, Pharmaceuticals, Pulmonology, Respiratory Infection, Sorafenib, Therapy, Thymic Cancer, Thymic Carcinoma, Thymoma, Treatment, Vascular Endothelial Growth Factor.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.